Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Research at St. Jude Children’s Research Hospital links common skin cancers with almost a 1 in 5 chance adult survivors of childhood cancer will develop another, more serious cancer
Childhood cancer survivors diagnosed later with non-melanoma skin cancer may be at increased risk for having a malignant tumor within 15 years, according to research led by St. Jude Children’s Research Hospital investigators.
Almost 20 percent of survivors in this Childhood Cancer Survivor Study (CCSS) who were diagnosed with basal or squamous cell skin cancer developed another more aggressive cancer within 15 years, said Gregory Armstrong, M.D., assistant member of the St. Jude Department of Epidemiology and Cancer Control. He will present the results June 7 at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago.
“These findings suggest non-melanoma skin cancers are a potential marker for survivors who are at risk for future invasive malignancies,” Armstrong said.
The study involved 14,358 childhood cancer survivors whose cancer was diagnosed between 1970 and 1986. All are now participating in the CCSS, which is funded by the National Cancer Institute to track the health outcomes of childhood cancer survivors. Armstrong is project director for CCSS, which includes investigators at 30 institutions in the U.S. and Canada. St. Jude is the central coordinating institution. Les Robison, Ph.D., St. Jude Epidemiology and Cancer Control chair, is the CCSS principal investigator. He is also this study’s senior author.
Childhood cancer survivors are known to be at increased risk for additional cancers, which remain a leading cause of disability and death among those who beat cancer the first time. “This study is the first to track the risk of multiple malignancies in a large group of aging cancer survivors,” Armstrong said. The average survivor in this study was age 36.
Nearly 10 percent of study participants, or 1,383 survivors, reported being diagnosed with a second tumor. The group included 231 survivors found to have a third tumor and 153 individuals diagnosed with four or more. The analysis found that nearly 39 percent of childhood survivors diagnosed with one subsequent tumor went on to develop another within 15 years.
The study’s other authors are Wei Lui, Ph.D., and Deokumar Srivastava, Ph.D., of St. Jude; Sue Hammond, M.D., Nationwide Children’s Hospital, Columbus, Ohio; Smita Bhatia, M.D., City of Hope, Duarte, CA.; Joseph Neglia, M.D., University of Minnesota, Minneapolis; Marilyn Stovall, Ph.D., M.D. Anderson Cancer Center, Houston; Wendy Leisenring, Sc.D., Fred Hutchinson Cancer Research Center, Seattle; and Yutaka Yasui, Ph.D., University of Alberta, Edmonton, Canada.
St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital is internationally recognized for its pioneering research and treatment of children with cancer and other catastrophic diseases. Ranked the No. 1 pediatric cancer hospital by Parents magazine and the No. 1 children’s cancer hospital by U.S. News & World Report, St. Jude is the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. St. Jude has treated children from all 50 states and from around the world, serving as a trusted resource for physicians and researchers. St. Jude has developed research protocols that helped push overall survival rates for childhood cancer from less than 20 percent when the hospital opened to almost 80 percent today. St. Jude is the national coordinating center for the Pediatric Brain Tumor Consortium and the Childhood Cancer Survivor Study. In addition to pediatric cancer research, St. Jude is also a leader in sickle cell disease research and is a globally prominent research center for influenza.
Founded in 1962 by the late entertainer Danny Thomas, St. Jude freely shares its discoveries with scientific and medical communities around the world, publishing more research articles than any other pediatric cancer research center in the United States. St. Jude treats more than 5,700 patients each year and is the only pediatric cancer research center where families never pay for treatment not covered by insurance. St. Jude is financially supported by thousands of individual donors, organizations and corporations without which the hospital’s work would not be possible. In 2010, St. Jude was ranked the most trusted charity in the nation in a public survey conducted by Harris Interactive, a highly respected international polling and research firm.